Changes in<i>HER2</i>Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and<sup>18</sup>F-Labeled Affibody Molecules
Gabriela Krämer-Marek(Institute of Cancer Research), Jacek Capala(National Cancer Institute)
Cited by 97
Related Papers
Targeted Radionuclide Therapy: Practical Applications and Future Prospects
|Biomarkers in Cancer|2016|50
Immunomodulatory activity of IR700-labelled affibody targeting HER2
|Cell Death and Disease|2020|35